Alpha-melanocyte-stimulating hormone (α-MSH) and adrenocorticotropic hormone (ACTH), peptides derived from the precursor proopiomelanocortin, share amino acid homology at the aminoterminus of ACTH, occur within the pituitary and the brain and are potent antipyretic compounds in cytokine-mediated fever. Because α-MSH and ACTH act within the hypothalamus to block leukocytic pyrogen- or cytokine-mediated fever, we hypothesized that these compounds might also be capable of blocking the action of interleukin-1 (IL-1) and interleukin-6 (IL-6) to stimulate corticotropin-releasing factor (CRF) release from the hypothalamus. Mediobasal hypothalami (MBH) were incubated in vitro. After 60 min preincubation in Krebs-Ringer bicarbonate buffer (KRB), MBH explants were incubated for 30 min with KRB alone or KRB containing IL-6 (10–13M), IL-1 (10–16–10–10 M) and/or ACTH1–24 (10–15–10–9M) or α-MSH (10–15-10–8M); CRF release into the incubation medium was measured by RIA. None of the ACTH1–24 or α-MSH concentrations changed basal CRF release significantly. As we reported previously, IL-6 (10–13M) increased CRF release; this increase was suppressed, in a dose-dependent fashion, by α-MSH at concentrations of 10–13–10–11M, with the maximal inhibitory effect observed at 10–13M. ACTH1–24 also exerted a dose-dependent inhibitory effect on IL·6-stimulated CRF release but at even lower concentrations (10–15–10–13M) with the maximal inhibitory effect observed with the 10–l4M concentration. Interleukin-1 β (IL-1β) evoked a bell-shaped, concentration-dependent increase in CRF secretion with a maximal effective concentration of 10–15M, 100 times lower than that previously reported for IL·6. IL-1β-induced CRF release was suppressed with a U-shaped concentration-dependent curve by α-MSH, with the maximal inhibitory effect observed with concentrations of 10–13 and 10–14M α-MSH. The results show that α-MSH is a potent inhibitor of IL-1β- and IL·6-induced CRF release from the hypothalamus in vitro and that ACTH1–24 is even more potent than α-MSH (which is ACTH1–13) in the blockade of IL·6-induced CRF release. These findings strongly support the concept of the anticytokine action of α-MSH.

Keywords:
Medial basal hypothalamic, Incubation, ACTH, L-1β, α-MSH and ACTH receptors
This content is only available via PDF.
© 1993 S. Karger AG, Basel
1993
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.